
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. (BDTX)
WebsitePrice
Market cap
Next catalystPotential Phase 3 initiation in Q2 2027, following sufficient Cohort 4 safety-data submission and subject to financingSilevertinib — planned global Phase 3 in frontline EGFR-NCM NSCLC · Trial initiationCompany release ↗
Cash
Chart & Events
Core Clinical
PreINDP1P2FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
PreINDP1P2FilingApproved
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Partner / License out
History / paused
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
BDTX PR & News
PR & News
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.